Andrew Pecora, M.D.

Dr. Pecora is the chief medical officer of NeoStem, Inc. Leading up to its merger with NeoStem, Dr. Pecora was the chairman and chief executive officer for Progenitor Cell Therapy, LLC (PCT), now a wholly owned subsidiary of NeoStem. He was a member of PCTs’ Board of Managers prior to its merger with NeoStem and was appointed to the NeoStem Board of Directors in December 2011.

Dr. Pecora currently serves as vice president of Cancer Services and chief innovations officer of the John Theurer Cancer Center at Hackensack University Medical Center (HUMC), and co-managing partner of the Northern New Jersey Cancer Center that is a private physicians practice group affiliated with HUMC.

Dr. Pecora has worked with numerous companies in developing their products and manages a large clinical practice and cancer department at a major health care institution. Dr. Pecora currently serves as chairman of the Board of Directors of Tetralogics, a private venture-funded biotechnology company developing small molecules for cancer therapy and on the Board of Directors of Cancer Genetics, a private venture-funded cancer diagnostics company. Dr. Pecora also has significant experience in the design of clinical trials (Phase I to III), institutional review board practices, conducting clinical trials, clinical research, and in payor relationships both domestically and internationally.

Dr. Pecora is a professor of medicine at the University of Medicine and Dentistry of New Jersey. He is a scientific advisor for numerous state, national, and international organizations, and serves on the Board of Directors for the American Society for Blood and Marrow Transplantation.

Dr. Pecora received his medical degree from the University of Medicine and Dentistry of New Jersey, graduating with honors. He went on to complete his medical education in internal medicine at New York Hospital and in hematology and oncology at Memorial Sloan-Kettering Cancer Center, both in New York City. He is board certified in internal medicine, hematology, and oncology.

Comments are closed.